A pharmaceuticals company based in Pasadena announced today that a drug they are developing to combat neurodegenerative disorders has successfully slowed down the progression of ALS in a clinical test and can modify genes associated with the nervous system.
ALS, amyotrophic lateral sclerosis, is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord.
Genervon Biopharmaceuticals provided data to an external contract research organization that confirmed the drug — known as GM6 — can edit genes in the nervous system that have an impact on defense against stress and upkeep of cellular balance, according to a statement released to the media.
About 1,200 genes showed a strong response to GM6 treatment, based on the most stringent of statistical thresholds, according to the press release. Using a less conservative criteria, approximately 3,000 genes showed change.
These numbers affirm that GM6 has major regulatory effects in neuronal cells and can be classified as a “master regulator” of the human CNS, according to the media statement.
Read more: http://www.pasadenanow.com/main/pasadena-drug-company-says-their-successfully-slows-down-progression-als/#.WB9gBC0rK1s